Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's Lymphoma: a systematic review and economic evaluation

Beverley Wake, Christopher Hyde, Stirling Bryan, Pelham Barton, Fujian Song, Anne Fry-Smith, Clare Davenport

Research output: Contribution to journalArticle

21 Citations (Scopus)
Original languageEnglish
Pages (from-to)1-85
Number of pages85
JournalHealth Technology Assessment
Issue number3
Publication statusPublished - 1 Jan 2002

Cite this